Filing identity and reporting period
The supplied document is Isoray, Inc.’s Form 10-K for the fiscal year ended June 30, 2021—not a Perspective Therapeutics filing or a 2020 Q4 report. It includes unaudited quarterly results through the quarter ended June 30, 2021. Isoray traded as ISR on NYSE American.
Business context
Isoray develops, manufactures, and sells Cesium-131 brachytherapy seeds and delivery formats for cancer treatment. Prostate cancer remained its largest market; other applications included brain, lung, gynecological, and head-and-neck cancers. Fiscal 2021 sales were overwhelmingly domestic.
Financial results and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Net sales | $10.053 million | $9.680 million |
| Gross profit / margin | $5.121 million / 50.9% | $5.124 million / 52.9% |
| Operating loss | $3.446 million | $3.476 million |
| Net loss | $3.387 million | $3.446 million |
| Operating cash flow | $(2.837) million | $(3.641) million |
| Cash and cash equivalents at year-end | $63.828 million | $2.392 million |
| Working capital / current ratio | $65.501 million / 37.37 | $3.932 million / 3.50 |
Operating expenses totaled $8.567 million, down slightly from $8.600 million. The company reported $3.010 million in total liabilities, including lease liabilities and an asset-retirement obligation; the filing does not report borrowings or other financial debt. Net cash increased $61.437 million, primarily because of financing proceeds. The company raised $56.375 million net from underwritten stock offerings and received $7.784 million from warrant exercises and $0.534 million from option exercises. Shares outstanding rose from 68.9 million at June 30, 2020 to 141.9 million at June 30, 2021.
Material changes versus the prior year
- Sales increased 4%. Other cancer-related sales rose 68% to $2.229 million, while prostate sales fell 6% to $7.824 million. Prostate represented 78% of FY2021 sales versus 86% in FY2020.
- Gross profit was nearly unchanged despite higher sales; gross margin declined about 2 percentage points, reflecting higher labor and material costs, freight expense, and unused isotope inventory.
- Net loss narrowed modestly, and cash used in operations declined. The large increase in cash and working capital followed substantial equity financing, rather than operating cash generation.
- GT Medical Technologies accounted for 11.3% of FY2021 revenue, compared with less than 10% in FY2020; the filing also reports significant revenue concentration among a physician practice/facilities and other major customers.
Outlook, risks, and unusual items
Management forecast a 25% revenue increase for FY2022 and estimated cash-flow break-even in three to four years if growth targets are met and no extraordinary expenses arise. These are targets, not assurances. The company expects increased isotope-related costs during the first half of FY2022 as it works to establish a second supply route.
- Supply concentration: Cesium-131 supply depended on Russian sources, and reactor outages, shipping disruptions, sanctions, or supplier problems could affect production. A September 2021 arrangement involving enriched barium and third parties was intended to mitigate supply risk, but execution and volumes were not assured.
- COVID-19 and demand: Pandemic-related restrictions and hospital capacity pressures delayed or canceled procedures and constrained customer access; future effects, including variants, were uncertain.
- Market and reimbursement: Prostate brachytherapy faces competition from external-beam radiation, surgery, and other treatments. Reimbursement levels and adoption of newer non-prostate applications remain uncertain. CMS had proposed removing brachytherapy from the Radiation Oncology Model; management was evaluating the potential impact.
- Execution and concentration: The business relies on one product, a concentrated customer base, clinical acceptance, and successful commercialization by partners, including GT Medical. GammaTile-related sales growth was not assured.
- Other disclosures: The filing reports no legal proceedings and no off-balance-sheet arrangements. The company remained loss-making, with an accumulated deficit of $91.325 million. The independent auditor issued an unqualified opinion and reported no critical audit matters; management stated internal controls were effective.
Key facts for investors to verify
- Confirm the issuer and period: this is Isoray’s FY2021 10-K, not a Perspective Therapeutics filing or FY2020 Q4 filing.
- Review the FY2022 revenue-growth target and assumptions underlying management’s three-to-four-year cash-flow break-even estimate.
- Track whether the alternative Russian isotope supply arrangement is completed, delivers expected quantities, and controls costs.
- Assess customer concentration, GT Medical’s sales performance, and the sustainability of growth in non-prostate applications.
- Monitor gross-margin trends, ongoing operating cash burn, future financing needs, and dilution following the FY2021 equity offerings.
- Check final CMS reimbursement rules and whether treatment volumes recover from pandemic-related disruption.